文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

基于数据挖掘的48例重症监护病房新型冠状病毒肺炎患者中药用药规律研究

[Study on medication laws of traditional Chinese medicine of 48 patients with coronavirus disease 2019 in intensive care unit based on data mining].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2021-01-01
一句话结论48例ICU新冠患者146张中药处方数据挖掘显示,核心药物为茯苓、柴胡、陈皮、白术、藿香、苦杏仁、黄芩、石膏、麻黄、甘草,治则以化浊解毒、益气养阴为主。

该研究纳入2021年1月7日至3月4日河北省胸科医院ICU收治的48例新冠肺炎患者,收集中药处方并用古今医案云平台(V2.2.1)进行频数、关联、聚类和复杂网络分析。共纳入146张有效处方,涉及59首方剂和115味中药,常用方剂为清肺排毒汤(30次,20.55%)、宣白承气汤(10次,6.85%)和大元饮(10次,6.85%)。常用中药为甘草(80次,54.79%)、茯苓(76次,52.05%)等,核心药物为茯苓、柴胡、陈皮、白术、藿香、苦杏仁、黄芩、石膏、麻黄、甘草。作者认为中老年新冠患者伴气虚毒侵,治则以化浊解毒、益气养阴为主。

要点

  • 48例ICU新冠患者中普通型17例、重型25例、危重型6例,平均年龄(62.4±13.7)岁,多合并高血压、冠心病、糖尿病、慢性阻塞性肺疾病等基础病。
  • 146张处方中最常用方剂为清肺排毒汤(30次,20.55%)、宣白承气汤(10次,6.85%)、大元饮(10次,6.85%)。
  • 最常用中药为甘草(80次,54.79%)、茯苓(76次,52.05%)、石膏(70次,47.95%)、苦杏仁(70次,47.95%)、麻黄(57次,39.04%)。
  • 关联分析支持度前3的药对为苦杏仁-石膏(0.43)、麻黄-苦杏仁(0.38)、陈皮-茯苓(0.36),麻黄-石膏支持度0.36。
  • 聚类分析得到3组聚类方,核心药物为茯苓、柴胡、陈皮、白术、藿香、苦杏仁、黄芩、石膏、麻黄、甘草。

适用人群与场景

  • 2021年1月7日至3月4日河北省胸科医院(河北省新冠肺炎定点医院)ICU收治、由河北省中医院重症团队治疗的48例确诊新冠肺炎患者。
  • 48例中男性20例、女性28例,平均年龄(62.4±13.7)岁;普通型17例、重型25例、危重型6例;多数合并高血压、冠心病、糖尿病、慢性阻塞性肺疾病等基础病。

研究设计与关键结果

  • 研究类型为基于古今医案云平台(V2.2.1)的数据挖掘研究,纳入48例ICU新冠肺炎患者,共146张有效处方,涉及59首方剂和115味中药。
  • 频数分析显示常用方剂为清肺排毒汤(30次,20.55%)、宣白承气汤(10次,6.85%)、大元饮(10次,6.85%)。
  • 常用中药为甘草(80次,54.79%)、茯苓(76次,52.05%)、石膏(70次,47.95%)、苦杏仁(70次,47.95%)、麻黄(57次,39.04%)、黄芩(56次,38.36%)、陈皮(53次,36.30%)、藿香(50次,34.25%)、白术(50次,34.25%)、柴胡(43次,29.45%)。
  • 功效以清热解毒(129次)、清热泻火(129次)、利湿(110次)为主;药性以温(509次)、平(287次)、寒(235次)为主;药味以辛(765次)、甘(654次)、苦(626次)为主;归经以肺(1 096次)、脾(785次)、胃(687次)为主。
  • 关联分析共得到17个药对,支持度前3为苦杏仁-石膏(0.43)、麻黄-苦杏仁(0.38)、陈皮-茯苓(0.36),麻黄-石膏支持度0.36。
  • 聚类分析得到3组聚类方:第一组麻黄、苦杏仁、石膏;第二组藿香、茯苓、陈皮、白术;第三组黄芩、甘草、枳实、泽泻、柴胡、生姜、桂枝。复杂网络分析核心药物为茯苓、柴胡、陈皮、白术、藿香、苦杏仁、黄芩、石膏、麻黄、甘草。

证据类型、等级与局限

  • 证据类型:基于医院ICU患者中药处方的数据挖掘研究(频数分析、关联分析、聚类分析、复杂网络分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为中老年新冠肺炎患者伴气虚毒侵,病机演变迅速,湿浊毒邪常困阻肺脾、气机失调,甚至内陷营血、耗伤阴阳。
  • 作者认为治疗以化浊解毒为基,益气养阴为治则,使邪去正复。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To analyze the data of Chinese medicine prescriptions for the treatment of coronavirus disease 2019 (COVID-19) in Shijiazhuang City, Hebei Province, with a view to further guide the clinical use of Chinese medicine in the prevention and treatment of COVID-19.

METHODS: Forty-eight patients diagnosed with COVID-19 who were treated by critical care team of Hebei Traditional Chinese Medicine Hospital in the intensive care unit (ICU) of Hebei Chest Hospital (Hebei Provincial COVID-19 designated hospital) from January 7 to March 4, 2021, were enrolled in this study. The patients' gender, age, clinical classification, past history, and all Chinese medicine prescriptions for the first visit and follow-up visits during the hospitalization were collected. A database was established based on the Ancient and Modern Medical Records Cloud Platform (V2.2.1), and the methods of frequency analysis, correlation analysis, cluster analysis, and complex network analysis were used to analyze the prescriptions of traditional Chinese medicine.

RESULTS: Among the 48 patients with COVID-19, 20 were males and 28 were females; the average age was (62.4±13.7) years old. The patients' condition was generally severe, including 17 cases of common type, 25 cases of severe type, and 6 cases of critical type, most of whom were combined with hypertension, coronary heart disease, diabetes, chronic obstructive pulmonary disease and other basic illnesses. A total of 146 valid prescriptions were included, involving 59 prescriptions and 115 Chinese medicines. Frequency analysis of 146 prescriptions showed that the commonly used prescriptions for patients with COVID-19 were Qingfei Paidu decoction (30 times, 20.55%), Xuanbai Chengqi decoction (10 times, 6.85%), and Dayuan Yin (10 times, 6.85%). The common Chinese medicines were liquorice (80 times, 54.79%), tuckahoe (76 times, 52.05%), gypsum (70 times, 47.95%), bitter almond (70 times, 47.95%), ephedra (57 times, 39.04%), scutellaria (56 times, 38.36%), tangerine peel (53 times, 36.30%), patchouli (50 times, 34.25%), atractylodes macrocephala (50 times, 34.25%), and bupleurum (43 times, 29.45%). The main effects were clearing heat and detoxification (129 times), clearing heat-fire (129 times) and eliminating dampness and diuresis (110 times). The medicinal properties were mainly warm (509 times), flat (287 times), and cold (235 times). The medicinal tastes were mainly pungent (765 times), sweet (654 times), and bitter (626 times). The medicinal channel tropism were mainly lung (1 096 times), spleen (785 times), and stomach (687 times). The correlation analysis showed that there were 17 drug combinations in total, among which the top 3 drug pairs in support were bitter almond-gypsum (0.43), ephedra-bitter almond (0.38), tangerine peel-poria (0.36), and ephedra-gypsum (0.36). Cluster analysis showed that there were 3 groups of clustering formulas. The first group was ephedra, bitter almond, and gypsum. The second group was patchouli, tuckahoe, tangerine peel, and atractylodes macrocephala. The third group was scutellaria, licorice, immature orange fruit, oriental waterplantain rhizome, bupleurum, ginger, and cassia twig. The core drugs were composed of tuckahoe, bupleurum, tangerine peel, atractylodes macrocephala, patchouli, bitter almond, scutellaria, gypsum, ephedra, and licorice.

CONCLUSIONS: Middle-aged and elderly patients with COVID-19 are accompanied by Qi deficiency and internal invasion of toxins, and the pathogenesis evolves rapidly. Damp and turbid toxins often block the lungs and trap the spleen, leading to disorder of Qi movement, and even invaginate Ying and Xue, drain Yin and Yang. The treatment is based on removing turbidity and detoxification, and replenishing Qi and nourishing Yin are the principle treatments, so that the evil is eliminated and the Qi is restored.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Liu Y, Mei J, Chen F, et al. [Study on medication laws of traditional Chinese medicine of 48 patients with coronavirus disease 2019 in intensive care unit based on data mining]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34955124. doi:10.3760/cma.j.cn121430-20210826-01285

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。